Does the media prefer FTLF or AYTU?

In the previous week, Aytu BioPharma had 8 more articles in the media than FitLife Brands. MarketBeat recorded 10 mentions for Aytu BioPharma and 2 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 0.93 beat Aytu BioPharma's score of -0.16 indicating that FitLife Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FitLife Brands 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PEPG or AYTU more profitable?

PepGen has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. PepGen's return on equity of -59.89% beat Aytu BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Aytu BioPharma -60.17% -69.93% -13.25%

Do analysts recommend AYTU or AIFC?

Aytu BioPharma currently has a consensus target price of $9.83, indicating a potential upside of 351.07%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Aytu BioPharma is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, AYTU or AIFC?

Aytu BioPharma has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aytu BioPharma $66.38M 0.35 -$13.56M -$4.58 N/A ALT5 Sigma $24.84M 4.34 -$344.51M N/A N/A

Is AYTU or AIFC more profitable?

Aytu BioPharma has a net margin of -60.17% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Aytu BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Aytu BioPharma -60.17% -69.93% -13.25% ALT5 Sigma -2,483.94% -68.25% -62.43%

Does the media refer more to AYTU or AIFC?

In the previous week, Aytu BioPharma had 5 more articles in the media than ALT5 Sigma. MarketBeat recorded 10 mentions for Aytu BioPharma and 5 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.38 beat Aytu BioPharma's score of -0.16 indicating that ALT5 Sigma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AYTU or TELO?

Aytu BioPharma currently has a consensus target price of $9.83, indicating a potential upside of 351.07%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Aytu BioPharma is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor AYTU or TELO?

In the previous week, Aytu BioPharma had 7 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 10 mentions for Aytu BioPharma and 3 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.45 beat Aytu BioPharma's score of -0.16 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Telomir Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, AYTU or BTMD?

biote has higher revenue and earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aytu BioPharma $66.38M 0.35 -$13.56M -$4.58 N/A biote $188.16M 0.48 $27.05M $0.44 5.46

Is AYTU or BTMD more profitable?

biote has a net margin of 8.29% compared to Aytu BioPharma's net margin of -60.17%. biote's return on equity of -25.72% beat Aytu BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Aytu BioPharma -60.17% -69.93% -13.25% biote 8.29% -25.72% 15.12%

Aytu BioPharma (AYTU) Competitors

$2.18 +0.03 (+1.40%)

As of 11:57 AM Eastern

Compare

AYTU vs. FTLF, PEPG, AIFC, TELO, and BTMD

Should you buy Aytu BioPharma stock or one of its competitors? MarketBeat compares Aytu BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aytu BioPharma include FitLife Brands (FTLF), PepGen (PEPG), ALT5 Sigma (AIFC), Telomir Pharmaceuticals (TELO), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

How does Aytu BioPharma compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

FitLife Brands has higher revenue and earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.29	$6.33M	$0.60	18.66
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A

FitLife Brands presently has a consensus target price of $21.50, suggesting a potential upside of 92.03%. Aytu BioPharma has a consensus target price of $9.83, suggesting a potential upside of 351.07%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

FitLife Brands has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 61.4% of FitLife Brands shares are held by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

FitLife Brands has a net margin of 6.64% compared to Aytu BioPharma's net margin of -60.17%. FitLife Brands' return on equity of 18.31% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

In the previous week, Aytu BioPharma had 8 more articles in the media than FitLife Brands. MarketBeat recorded 10 mentions for Aytu BioPharma and 2 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 0.93 beat Aytu BioPharma's score of -0.16 indicating that FitLife Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FitLife Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aytu BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

FitLife Brands beats Aytu BioPharma on 10 of the 16 factors compared between the two stocks.

How does Aytu BioPharma compare to PepGen?

PepGen (NASDAQ:PEPG) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Aytu BioPharma has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A

PepGen presently has a consensus target price of $11.60, indicating a potential upside of 670.76%. Aytu BioPharma has a consensus target price of $9.83, indicating a potential upside of 351.07%. Given PepGen's stronger consensus rating and higher possible upside, research analysts clearly believe PepGen is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

58.0% of PepGen shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PepGen has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

In the previous week, Aytu BioPharma had 9 more articles in the media than PepGen. MarketBeat recorded 10 mentions for Aytu BioPharma and 1 mentions for PepGen. PepGen's average media sentiment score of 0.94 beat Aytu BioPharma's score of -0.16 indicating that PepGen is being referred to more favorably in the media.

Company	Overall Sentiment
PepGen	Positive
Aytu BioPharma	Neutral

PepGen has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. PepGen's return on equity of -59.89% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Summary

PepGen beats Aytu BioPharma on 9 of the 15 factors compared between the two stocks.

How does Aytu BioPharma compare to ALT5 Sigma?

Aytu BioPharma (NASDAQ:AYTU) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Aytu BioPharma had 5 more articles in the media than ALT5 Sigma. MarketBeat recorded 10 mentions for Aytu BioPharma and 5 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.38 beat Aytu BioPharma's score of -0.16 indicating that ALT5 Sigma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aytu BioPharma has a net margin of -60.17% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Aytu BioPharma has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
ALT5 Sigma	$24.84M	4.34	-$344.51M	N/A	N/A

Aytu BioPharma has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

Aytu BioPharma currently has a consensus target price of $9.83, indicating a potential upside of 351.07%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Aytu BioPharma is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aytu BioPharma beats ALT5 Sigma on 10 of the 14 factors compared between the two stocks.

How does Aytu BioPharma compare to Telomir Pharmaceuticals?

Aytu BioPharma (NASDAQ:AYTU) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

In the previous week, Aytu BioPharma had 7 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 10 mentions for Aytu BioPharma and 3 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.45 beat Aytu BioPharma's score of -0.16 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telomir Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telomir Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Aytu BioPharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

33.5% of Aytu BioPharma shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Aytu BioPharma beats Telomir Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Aytu BioPharma compare to biote?

Aytu BioPharma (NASDAQ:AYTU) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Aytu BioPharma presently has a consensus price target of $9.83, suggesting a potential upside of 351.07%. biote has a consensus price target of $2.75, suggesting a potential upside of 14.44%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Aytu BioPharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, biote has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aytu BioPharma had 9 more articles in the media than biote. MarketBeat recorded 10 mentions for Aytu BioPharma and 1 mentions for biote. biote's average media sentiment score of 0.93 beat Aytu BioPharma's score of -0.16 indicating that biote is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
biote	Positive

biote has a net margin of 8.29% compared to Aytu BioPharma's net margin of -60.17%. biote's return on equity of -25.72% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
biote	8.29%	-25.72%	15.12%

biote has higher revenue and earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
biote	$188.16M	0.48	$27.05M	$0.44	5.46

Summary

biote beats Aytu BioPharma on 11 of the 16 factors compared between the two stocks.

Get Aytu BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AYTU vs. The Competition

Export

Metric	Aytu BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.39M	$3.40B	$6.50B	$12.37B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.48	20.08	24.01	24.71
Price / Sales	0.35	326.19	540.55	165.59
Price / Cash	5.73	53.61	27.48	37.92
Price / Book	1.03	8.11	10.55	6.85
Net Income	-$13.56M	$23.89M	$3.56B	$337.45M
7 Day Performance	-4.80%	3.36%	1.54%	2.70%
1 Month Performance	-0.46%	1.34%	2.48%	4.60%
1 Year Performance	11.79%	46.46%	26.49%	32.81%

Aytu BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AYTU Aytu BioPharma	3.0055 of 5 stars	$2.18 +1.4%	$9.83 +351.1%	+10.3%	$23.39M	$66.38M	N/A	160	News Coverage Analyst Revision Gap Up
FTLF FitLife Brands	4.5247 of 5 stars	$10.22 -1.4%	$21.50 +110.4%	-21.4%	$97.39M	$81.46M	16.92	20
PEPG PepGen	2.6561 of 5 stars	$1.38 +2.2%	$11.60 +740.6%	+2.8%	$93.38M	N/A	N/A	30
AIFC ALT5 Sigma	0.2909 of 5 stars	$0.68 +3.3%	N/A	-93.5%	$91.86M	$24.84M	N/A	170	Gap Up
TELO Telomir Pharmaceuticals	1.1221 of 5 stars	$1.21 -5.5%	N/A	-35.7%	$88.03M	N/A	N/A	1	News Coverage Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AYTU) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aytu BioPharma (AYTU) Competitors

AYTU vs. FTLF, PEPG, AIFC, TELO, and BTMD

How does Aytu BioPharma compare to FitLife Brands?

Summary

How does Aytu BioPharma compare to PepGen?

Summary

How does Aytu BioPharma compare to ALT5 Sigma?

Summary

How does Aytu BioPharma compare to Telomir Pharmaceuticals?

Summary

How does Aytu BioPharma compare to biote?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aytu BioPharma (AYTU) Competitors

AYTU vs. FTLF, PEPG, AIFC, TELO, and BTMD

How does Aytu BioPharma compare to FitLife Brands?

Which has stronger earnings and valuation, FTLF or AYTU?

Do analysts prefer FTLF or AYTU?

Which has more risk & volatility, FTLF or AYTU?

Do insiders and institutionals hold more shares of FTLF or AYTU?

Is FTLF or AYTU more profitable?

Does the media prefer FTLF or AYTU?

Summary

How does Aytu BioPharma compare to PepGen?

Which has stronger valuation and earnings, PEPG or AYTU?

Do analysts prefer PEPG or AYTU?

Do insiders & institutionals hold more shares of PEPG or AYTU?

Which has more risk and volatility, PEPG or AYTU?

Does the media favor PEPG or AYTU?

Is PEPG or AYTU more profitable?

Summary

How does Aytu BioPharma compare to ALT5 Sigma?

Does the media refer more to AYTU or AIFC?

Is AYTU or AIFC more profitable?

Which has preferable valuation and earnings, AYTU or AIFC?

Which has more volatility and risk, AYTU or AIFC?

Do analysts recommend AYTU or AIFC?

Do institutionals & insiders believe in AYTU or AIFC?

Summary

How does Aytu BioPharma compare to Telomir Pharmaceuticals?

Do analysts rate AYTU or TELO?

Which has stronger earnings and valuation, AYTU or TELO?

Does the media favor AYTU or TELO?

Is AYTU or TELO more profitable?

Which has more risk and volatility, AYTU or TELO?

Do insiders & institutionals hold more shares of AYTU or TELO?

Summary

How does Aytu BioPharma compare to biote?

Do analysts rate AYTU or BTMD?

Which has more volatility and risk, AYTU or BTMD?

Do insiders and institutionals have more ownership in AYTU or BTMD?

Does the media refer more to AYTU or BTMD?

Is AYTU or BTMD more profitable?

Which has stronger earnings & valuation, AYTU or BTMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools